slide1 n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Azienda ULSS 13 – Mirano VE PowerPoint Presentation
Download Presentation
Azienda ULSS 13 – Mirano VE

Loading in 2 Seconds...

play fullscreen
1 / 53

Azienda ULSS 13 – Mirano VE - PowerPoint PPT Presentation


  • 187 Views
  • Uploaded on

MULTIPLE TREATMENT CHOICES: ARE THEY EQUALLY ( cost ) EFFECTIVE?. Giovanni L. Pappagallo (giovanni.pappagallo@tin.it). Azienda ULSS 13 – Mirano VE. Dipartimento di Scienze Mediche U.O.C. di Oncologia & Ematologia Oncologica. Ufficio di Epidemiologia & Sperimentazioni Cliniche.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Azienda ULSS 13 – Mirano VE' - chana


Download Now An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

MULTIPLE TREATMENT CHOICES:

ARE THEY EQUALLY

(cost) EFFECTIVE?

Giovanni L. Pappagallo

(giovanni.pappagallo@tin.it)

Azienda ULSS 13 – Mirano VE

Dipartimento di Scienze Mediche

U.O.C. di Oncologia & Ematologia Oncologica

Ufficio di Epidemiologia & Sperimentazioni Cliniche

your treatment choice
YOUR TREATMENT CHOICE…

Statistical Significance

vs

Clinical Significance

Registrative Studies

vs

Therapeutic Strategies

Controlling

the Cost of Innovative

Cancer Therapeutics

your treatment choice1
YOUR TREATMENT CHOICE…

Statistical Significance

vs

Clinical Significance

RegistrativeStudies

vs

TherapeuticStrategies

Controlling

the Costof Innovative

CancerTherapeutics

poor clinical significance when
PoorClinicalSignificancewhen

PossibleClinicalSignificancealsowhen

P<0.05

  • Earlytermination
  • Overpowering
  • Inadequatecontrolgroup
  • Inadequate (?) primaryendpoint
  • Subgroupanalysis
  • P≥0.05
  • Underpowering
  • Inadequate(?) patientselection
slide13

target Δ of

HERA trial:

RRR 23%

HR 0.54

(95%CL 0.43-0.67)

Trastuzumab

better

Control

better

J Slutsman, ASCO 2005

slide14

HR 0.62

(95%CL

0.41-0.95)

target Δ of

CALGB 9633:

RRR 33%

CarboTaxol

better

Control

better

J Slutsman, ASCO 2005

poor clinical significance when1
PoorClinicalSignificancewhen

PossibleClinicalSignificancealsowhen

P<0.05

  • Earlytermination
  • Overpowering
  • Inadequatecontrolgroup
  • Inadequate (?) primaryendpoint
  • Subgroupanalysis
  • P≥0.05
  • Underpowering
  • Inadequate(?) patientselection
slide16

Target Δ: HR erlotinib:placebo = 0.75 (2 months OS improvement)

Analysis after 381 events (450 patients; α 5%, power 80%)

Analysis after 486 events (569 patients)

Actual difference:

0.33 months (10 days)

slide17

Target Δ: HR cetuximab:placebo = 0.80 (2.5 months OS improvement)

Analysis after 845 events (1100 patients; α 5%, power 90%)

Analysis after ??? events (1125 patients)

Actual difference:

1.2 months

poor clinical significance when2
PoorClinicalSignificancewhen

PossibleClinicalSignificancealsowhen

P<0.05

  • Earlytermination
  • Overpowering
  • Inadequatecontrolgroup
  • Inadequate (?) primaryendpoint
  • Subgroupanalysis
  • P≥0.05
  • Underpowering
  • Inadequate(?) patientselection
slide20

Equipoise?

“Standard” therapy?

slide21

Equipoise?

New “standard”?

“Standard” therapy?

poor clinical significance when3
PoorClinicalSignificancewhen

PossibleClinicalSignificancealsowhen

P<0.05

  • Earlytermination
  • Overpowering
  • Inadequatecontrolgroup
  • Inadequate (?) primaryendpoint
  • Subgroupanalysis
  • P≥0.05
  • Underpowering
  • Inadequate(?) patientselection
slide27

VALIDATION OF SURROGATE ENDPOINTS:“FULL CAPTURE OF EFFECT”

Effect of treatment on surrogate

Effect of surrogate on true endpoint

S

T

Trt

Effect of treatment on trueendpoint

must befullycaptured by surrogate

Prentice, Statist Med 1989;8:431.

slide28

VALIDATION OF SURROGATE ENDPOINTS:“FULL CAPTURE OF EFFECT”

Effect of treatment on surrogate

Effect of surrogate on true endpoint

S

T

Trt

Effect of treatment on trueendpoint

must befullycaptured by surrogate

Prentice, Statist Med 1989;8:431.

poor clinical significance when4
PoorClinicalSignificancewhen

PossibleClinicalSignificancealsowhen

  • P≥0.05
  • Underpowering
  • Inadequate(?) patientselection

P<0.05

  • Earlytermination
  • Overpowering
  • Inadequatecontrolgroup
  • Inadequate (?) primaryendpoint
  • Subgroupanalysis
poor clinical significance when5
PoorClinicalSignificancewhen

PossibleClinicalSignificancealsowhen

P<0.05

  • Earlytermination
  • Overpowering
  • Inadequatecontrolgroup
  • Inadequate (?) primaryendpoint
  • Subgroupanalysis
  • P≥0.05
  • Underpowering
  • Inadequate(?) patientselection
poor clinical significance when6
PoorClinicalSignificancewhen

PossibleClinicalSignificancealsowhen

P<0.05

  • Earlytermination
  • Overpowering
  • Inadequatecontrolgroup
  • Inadequate (?) primaryendpoint
  • Subgroupanalysis
  • P≥0.05
  • Underpowering
  • Inadequate(?) patientselection
competing causes of mortality

Breast-cancer deaths

Other deaths

Competing causes of mortality

Age ≥50 years and ER+

Probability

0.4

0.3

0.2

0.1

0.0

0

5

10

15

Time from diagnosis (years)

ER+, oestrogen receptor-positive

Hanrahan et al. J Clin Oncol 2007; 25: 4952-60

your treatment choice2
YOUR TREATMENT CHOICE…

StatisticalSignificance

vs

ClinicalSignificance

Registrative Studies

vs

Therapeutic Strategies

Controlling

the Cost of Innovative

Cancer Therapeutics

maintenance therapy in advanced nsclc proof of principle or ready to use strategy
MAINTENANCE THERAPY IN ADVANCED NSCLC: PROOF OF PRINCIPLEOR READY-TO-USE STRATEGY?

Only 19% of placebo ptsreceivedPemetrexed at anytime

Only 16% of placebo ptsreceivedErlotinib at anytime

C. Belani, ASCO 2009

F. Cappuzzo, WCLC 2009

your treatment choice3
YOUR TREATMENT CHOICE…

StatisticalSignificance

vs

ClinicalSignificance

RegistrativeStudies

vs

TherapeuticStrategies

Controlling

the Cost of Innovative

Cancer Therapeutics

your treatment choice4
YOUR TREATMENT CHOICE…

StatisticalSignificance

vs

ClinicalSignificance

RegistrativeStudies

vs

TherapeuticStrategies

Controlling

the Cost of Innovative

Cancer Therapeutics

your treatment choice5
YOUR TREATMENT CHOICE…

StatisticalSignificance

vs

ClinicalSignificance

RegistrativeStudies

vs

TherapeuticStrategies

Controlling

the Costof Innovative

CancerTherapeutics